Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;99(11):e19491.
doi: 10.1097/MD.0000000000019491.

Promoter hypermethylation of CD133/PROM1 is an independent poor prognosis factor for head and neck squamous cell carcinoma

Zele Hu  1 , Huigao Liu  1 , Xinrong Zhang  1 , Bin Hong  1 , Zhenhua Wu  2 , Qun Li  3   4   5 , Chongchang Zhou  3   4   5
Affiliations

Promoter hypermethylation of CD133/PROM1 is an independent poor prognosis factor for head and neck squamous cell carcinoma

Zele Hu et al. Medicine (Baltimore). 2020 Mar.

Abstract

PROM1 has played a pivotal role in the identification and isolation of tumor stem cells. This study aimed to assess the association between PROM1 promoter methylation and head and neck squamous cell carcinoma (HNSCC), and its diagnostic and prognostic value.Bioinformatic analysis was performed using data from the Cancer Genome Atlas-HNSC and Gene Expression Omnibus datasets.The results showed that PROM1 promoter was hypermethylated in HNSCCs compared with normal head and neck tissues (P = 4.58E-37). The area under the receiver-operating characteristic curve based on methylated PROM1 data was 0.799. In addition, PROM1 hypermethylation independently predicted poor overall survival (hazard ratio [HR]: 1.459, 95% confidence interval [CI]: 1.071-1.987, P = .016) and recurrence-free survival (HR: 1.729, 95% CI: 1.088-2.749, P = .021) in HNSCC patients. Moreover, PROM1 methylation was weakly negatively correlated with its mRNA expression (Pearson r = -0.148, P < .001).In summary, our study reveals that methylated PROM1 might serve as a valuable diagnostic biomarker and predictor of poor survival for HNSCC patients. PROM1 hypermethylation might partially contribute to its downregulation in HNSCC.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Genomic position of 3 available CpG probes (cg10630155, cg04203238, and cg26260038 in the Illumina Human Methylation 450K) in the PROM1 promoter is shown in the UCSC genome browser (human 2009 assembly; GRCh37/hg19).
Figure 2
Figure 2
HNSCC tissues have significantly elevated PROM1 promoter methylation levels compared with nontumor tissues. HNSCC = head and neck squamous cell carcinoma, N = sample number.
Figure 3
Figure 3
ROC curves to assess the diagnostic value of PROM1 promoter methylation in head and neck squamous cell carcinoma patients. The AUC was 0.799. The arrow indicates the cutoff point. ROC = receiver-operating characteristic, AUC = area under the curve.
Figure 4
Figure 4
Association between PROM1 promoter methylation and head and neck squamous cell carcinoma (HNSCC) prognosis. (A) PROM1 promoter hypermethylation is associated with poor overall survival in HNSCC patients. (B) PROM1 promoter hypermethylation is associated with poor recurrence-free survival in HNSCC patients.
Figure 5
Figure 5
PROM1 expression levels are significantly reduced in HNSCC tissues compared with normal tissues.
Figure 6
Figure 6
The correlation between PROM1 expression and its promoter methylation in HNSCC tissues and cell lines. (A) PROM1 expression was negatively correlated with its promoter methylation in HNSCC. (B) PROM1 expression increased in HNSCC cell lines after 5’-aza-2’-deoxycytidine treatment (5-AZA) treatment. ∗: fold change = with 5-AZA treatment/without 5-AZA treatment. HNSCC = head and neck squamous cell carcinoma, N = sample number.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Ann Rev Pathol 2009;4:49–70. - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34. - PubMed
    1. Kindt N, Descamps G, Lechien JR, et al. Involvement of HPV infection in the release of macrophage migration inhibitory factor in head and neck squamous cell carcinoma. J Clin Med 2019;8:pii: E75. - PMC - PubMed
    1. Shield KD, Ferlay J, Jemal A, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin 2017;67:51–64. - PubMed

Publication types

MeSH terms